ImmunoForge, a clinical-stage biopharmaceutical company focused on rare and muscular diseases, is positioning itself at the forefront of Central Nervous System (CNS) drug innovation with its proprietary LMT15 Platform. Designed as a next-generation Blood-Brain Barrier (BBB) shuttle, the platform aims to address longstanding challenges in delivering therapeutics effectively to the brain.

The LMT15 Platform is built on Leptin receptor-mediated transcytosis, a targeted mechanism that enables improved drug permeability across the BBB. By utilising this pathway, the company claims the technology offers enhanced delivery efficiency while reducing potential systemic side effects compared to conventional approaches.

A defining feature of the platform is its integration with the company’s Elastin-Like Polypeptide (ELP) technology. This combination creates a single-structure modality that not only facilitates efficient BBB penetration but also enables a once-monthly long-acting formulation. The dual capability is expected to expand possibilities in CNS therapeutics as well as in metabolic and obesity-related treatments.

The platform recently gained global recognition after the company secured first place at the Novo Nordisk Partnering Day 2026, an open innovation initiative co-hosted by Novo Nordisk, Korea Health Industry Development Institute and Novo Holdings. The recognition followed a competitive evaluation and final pitch round among multiple biotech participants.

As part of the award, ImmunoForge will receive mentorship, expert feedback and opportunities for collaboration, strengthening its pathway towards commercialisation and global partnerships. The company has indicated plans to pursue joint research initiatives and technology transfer agreements to expand the application of its platforms across therapeutic areas.

Earlier this year, ImmunoForge filed a patent for the LMT15 platform and has initiated full-scale development of its CNS-focused pipeline. Alongside its platform technologies, the company is advancing clinical-stage programmes including PF1801, currently in Phase II trials for polymyositis and dermatomyositis, and PF1804 for Duchenne muscular dystrophy cardiomyopathy, which has received investigational new drug approval and orphan drug designation from the U.S. Food and Drug Administration.

With continued progress across its pipeline and platform technologies, the company aims to expand treatment options for patients with rare, muscular and neurological conditions, while addressing key limitations in drug delivery to the brain.